More stories

  • in

    UnitedHealth stock jumps after earnings top estimates despite rising medical costs

    UnitedHealth Group’s stock price jumped after the health-care conglomerate reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations.
    The company also raised the low end of its full-year adjusted earnings outlook. 
    The results eased investor concerns after UnitedHealth flagged a surge in demand for non-urgent surgeries and outpatient services last month.

    Representatives speak with customers at a UnitedHealthcare store in Queens, New York.
    Michael Nagle | Bloomberg | Getty Images

    UnitedHealth Group’s stock price jumped Friday after the health-care conglomerate reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations despite rising medical costs.
    The results eased investor concerns after the Minnesota-based company flagged a surge in demand for non-urgent surgeries and outpatient services last month and spooked the market.

    related investing news

    Shares of UnitedHealth closed up more than 7% Friday. The stock is down more than 9% so far this year, however.
    UnitedHealth Group is the biggest health-care company in the U.S. by market cap and revenue, and is even bigger than the nation’s largest banks. Given its size, UnitedHealth Group is considered a bellwether for the broader health insurance sector. Its market value was around $447 billion as of Friday’s close.
    Here’s what UnitedHealth Group reported compared with Wall Street’s expectations, based on a survey of analysts by Refinitiv:

    Earnings per share: $6.14 adjusted vs. $5.99 expected 
    Revenue: $92.9 billion vs. $91.01 billion expected

    UnitedHealth Group reported a net income of $5.47 billion, or $5.82 per share, for the quarter. That compares with $5.07 billion, or $5.34 per share, for the same period a year ago. Excluding certain items, the company’s adjusted earnings per share were $6.14 for the period. 
    The company reported total revenue of $92.9 billion for the quarter, up 16% from the same period a year ago. That excludes $33.6 billion in “eliminations,” which are payments from the company’s UnitedHealthcare business to its other division, Optum. UnitedHealth Group can’t record those transactions as revenue because it is paying itself.

    UnitedHealthcare, which provides insurance coverage and benefits services to more than 50 million people, saw second-quarter revenue grow 13% from a year ago to $70.2 billion. 
    The company’s other platform, Optum, saw revenue increase nearly 25% from a year ago to $56.3 billion. Optum offers health services and runs one of the largest pharmacy benefit managers, or middlemen who negotiate drug discounts with drug manufacturers on behalf of health insurers and large employers.
    Optum’s growth was helped in part by UnitedHealth Group’s roughly $8 billion acquisition of the health care technology company Change Healthcare.
    It was also driven by a more than 900,000 year-over-year increase in the number of patients served by Optum’s health services business under value-based care arrangements.
    UnitedHealth Group raised the low end of its full-year adjusted earnings outlook to $24.70 to $25.00 per share, from a previous forecast of $24.50 to $25.00 per share. 
    The company’s medical cost ratio – the percentage of payout on claims compared with premiums – came in at 83.2%. Analysts had estimated that ratio would be 83.3% for the quarter, according to FactSet. 
    The medical cost ratio is up almost 2% from the same period a year ago. UnitedHealth Care said that was driven by the previously noted uptick in elective surgeries and outpatient care activity, primarily among seniors. 
    “To illustrate, in the second quarter, outpatient care activity among seniors was a few hundred basis points above our expectations,” UnitedHealth Group CFO John Rex said during an earnings call.
    Rex noted that much of that care has come from seniors who are getting heart procedures and hip and knee replacements at outpatient clinics, reiterating his previous remarks at the Goldman Sachs health-care conference last month.
    UnitedHealth Group expects its medical cost ratio to “be a little bit lower” in the third quarter compared with the second quarter, Rex said during the call.
    He added that the company also expects the medical cost ratio in the third quarter to be “higher marginally” than it will be in the fourth quarter, noting that it’s “just a seasonality factor.”
    But overall, the company expects the “general pacing of care activity to remain consistent,” according to Rex.
    Insurance companies have benefited in recent years from a delay in nonurgent procedures due to hospital staffing shortages and the pandemic, which saw hospitals inundated with Covid patients. Hospitals at that time were widely seen as too risky to enter for elective procedures.
    But UnitedHealth Group executives indicated that the trend may be reversing. More

  • in

    Stocks making the biggest moves midday: UnitedHealth, JPMorgan Chase, Microsoft, JetBlue and more

    A UnitedHealth Group health insurance card is seen in a wallet, Oct.14, 2019.
    Lucy Nicholson | Reuters

    Check out the companies making headlines in midday trading.
    JPMorgan Chase — Shares inched 0.6% higher after the bank reported stronger-than-expected results for the second quarter, as it benefited from higher interest rates and better-than-expected bond trading.

    related investing news

    3 hours ago

    2 days ago

    Wells Fargo — Wells Fargo shares dipped slightly even after the Wall Street firm topped second-quarter expectations. The bank also said it anticipates higher-than-expected net interest income this year.
    UnitedHealth — The health-care giant popped 7.2% after topping expectations for the second quarter on both the top and bottom lines. UnitedHealth also upped the lower end of its full-year guidance. Other health-care stocks rose in sympathy, with Cigna and Elevance Health last up more than 4% each.
    Citigroup — Shares of the New York-based lender fell 4% even after the firm reported second-quarter earnings and revenue that topped expectations. Despite the beat, Citi’s revenue fell 1% from a year ago as the decline in markets and investment banking businesses weighed on its results.
    JetBlue Airways, American Airlines — JetBlue Airways and American Airlines slid 3.8% and 1.7%, respectively. The two airlines are no longer selling seats on each other’s flights after Thursday, following a court ruling in May that they end their more than two-year partnership.
    Microsoft — The software stock finished 0.8% after UBS upgraded it to a buy rating, saying its artificial intelligence opportunity and recent underperformance make it too attractive to ignore.

    AT&T — The telecommunications stock sank 4.1% after JPMorgan downgraded it to neutral from overweight, citing competition concerns. The Wall Street firm also said AT&T’s exposure to cable may limit the upside for shares.
    State Street — Shares slumped 12.1% after the financial giant’s second-quarter revenue of $3.11 billion missed analyst estimates of $3.14 billion, per Refinitiv. However, State Street beat on earnings, reporting earnings per share of $2.17, versus the $2.10 expected by analysts.
    Blackrock — Shares of the asset manager lost 1.6% after reporting second-quarter results. Earnings topped Wall Street’s expectations, but net inflows came up short and showed a decline.
    Alcoa — The aluminum stock fell 5.9% following a downgrade to neutral from overweight by JPMorgan. The firm said the stock could struggle as the price for the metal faces downward pressure.
    Progressive — Progressive shares gained 1.8%, reversing prior losses, after Wells Fargo downgraded the insurance company to equal weight from overweight, citing growth concerns.
    Eli Lilly — The pharmaceutical stock rose 3.5% in midday trading. Eli Lilly said it plans to acquire privately held obesity drug maker Versanis for $1.9 billion.
    — CNBC’s Yun Li, Alex Harring, Sarah Min and Michelle Fox contributed reporting. More

  • in

    How you can save $500 or more on a flight to Europe this year

    Summer 2023 is the most expensive on record to fly to Europe.
    Buying a round-trip international flight to Europe for travel in the fall can yield savings of $500 a ticket, on average, relative to summer departure, according to Hopper.
    The “shoulder season” around September and October is generally less expensive.
    Cities such as Rome, London, Paris and Barcelona have been top destinations for Americans. Travel abroad ramped up as Covid-19 restrictions eased.

    Jose A. Bernat Bacete | Moment | Getty Images

    Airfare to Europe hit an all-time high this summer. But those dissuaded by the sticker shock can still travel overseas in coming months and cut costs by perhaps hundreds of dollars a ticket.
    Flying to Europe from the U.S. during the fall “shoulder season” — in September and October — instead of in the summer will save the average traveler $500 per round-trip ticket, according to data from Hopper, a travel app.

    Europe is the most popular overseas destination for U.S. tourists this summer. But travelers to top European cities would save 34%, on average, by going in the fall instead of June, July or August, Hopper found.
    More from Personal Finance:Canceled or delayed flight? What to know about your rightsU.S. passport delays may be months longTravel to Europe is no longer a ‘screaming, bargain-basement’ deal
    Consider these examples: Airfare to Rome is $1,284, on average, this summer. It’s $736 this fall, a 43% reduction, or $548 of savings per ticket.
    Likewise, those venturing to London would pay $693 in the fall, 32% less than summer’s $1,025. In Barcelona, visitors would fly for $757 in the fall, versus $1,193 in the summer, a 37% savings.
    “There is some good news in sight,” Hayley Berg, Hopper’s lead economist, said of prices.

    Shoulder-season travel is typically less expensive

    Shoulder season is generally a less expensive time to travel. But the savings may be especially noteworthy to prospective buyers due to recent nosebleed costs, experts said.
    The price dynamic is guided by supply and demand: Fewer people typically travel in the fall, as kids return to school, for example.
    That also means not everyone — such as families with kids, or workers such as teachers whose vacations revolve around summer months — may be able to take advantage of a bargain.  
    But those who can travel during the shoulder season would likely get a better overall experience due to milder weather and reduced crowds, said Sally French, a travel expert at NerdWallet.

    Why international travel costs are so high

    Tourists and locals at the crowded El Postiguet Beach in Alicante, Spain, July 9, 2023.
    Marcos Del Mazo | Lightrocket | Getty Images

    Costs to travel abroad have soared in 2023 as people who put off international trips during the Covid-19 pandemic indulge their pent-up wanderlust. There has been historic demand for passports and applications for federal travel programs such as Global Entry.
    Many Covid-era restrictions have eased, making it easier to go overseas. For example, the U.S. ended a testing requirement for international travelers in June 2022.
    Some countries’ borders were still closed last summer, especially those in Asia. Now, just seven nations have some kind of travel restriction in place for vaccinated American travelers, according to Kayak. For unvaccinated American travelers, the number rises to 23.
    “This is the first year people don’t have many Covid requirements at all,” French said.

    The Colosseum at sunrise in Rome.
    Alexander Spatari | Moment | Getty Images

    As a result, summer 2023 is the most expensive time on record to travel to Europe, Hopper said. The average ticket costs about $1,200, eclipsing the previous high in 2018 by $50 a ticket.
    In Asia, the No. 2 most-popular destination for Americans, average prices are 64% higher than pre-pandemic levels, Berg said.
    It’s not just airfare. Staying at a European hotel this summer costs $205 a night, a 37% increase from last year. Cities such as Rome and Madrid have seen prices jump 63% and 41%, respectively, over the last year, Hopper said.

    Price doesn’t seem to have dissuaded travelers, in the aggregate, from travel abroad, however.
    That makes sense from a money standpoint. The typical American tourist going abroad tends to be wealthier — with an average household income of $110,000 relative to $83,000 for all travelers — and much more optimistic about their personal finances, spilling over into a greater willingness to spend on leisure travel, according to a recent poll by Destination Analysts, a tourism market research firm.

    Other travel tips to scout a good deal

    Senja island, Norway.
    Roberto Moiola / Sysaworld | Moment | Getty Images

    Aside from traveling during the off-season, here are some general tips from travel experts on finding a good deal.

    Be flexible. Travel midweek (e.g., Tuesday and Wednesday) instead of during the weekend. Consider alternate locations, perhaps a destination such as Scandinavia instead of the most popular cities such as Paris and Rome. Play around with dates and locations using tools such as Google Flights and Explore.
    Don’t book flights at the last minute. Book an international flight a few months ahead, if possible.
    Use rewards. Now is a good time to use, and not hoard, any frequent flier miles or other benefits.
    Leverage credit card benefits. Your credit card may have perks for travel or rental-car insurance, or another benefit. Purchase part or all of a vacation with that card, and you may not need to buy separate insurance.
    Keep other costs in mind. If you find a good deal on airfare, don’t overlook other costs such as lodging before booking. They may amount to a bigger cost than airfare, depending on the length of stay and destination. More

  • in

    FDA says soda sweetener aspartame is safe, disagreeing with WHO finding on possible cancer link

    The U.S. Food and Drug Administration disagrees with the World Health Organization’s classification of the soda sweetener aspartame as possibly carcinogenic to humans.
    The FDA said the studies WHO experts relied on to make this conclusion had “significant shortcomings.”
    FDA scientists have no safety concerns about aspartame when the sugar substitute is consumed within the daily recommended limit.

    Cans of PepsiCo’s Pepsi Zero Sugar soda are displayed for an arranged photograph taken in Tiskilwa, Illinois, on Wednesday, April 17, 2019.
    Daniel Acker | Bloomberg | Getty Images

    The U.S. Food and Drug Administration disagrees with a World Health Organization finding that the widely used soda sweetener aspartame possibly causes cancer in humans, saying the studies used to reach that conclusion had “significant shortcomings.”
    “Aspartame is one of the most studied food additives in the human food supply. FDA scientists do not have safety concerns when aspartame is used under the approved conditions,” an agency spokesperson said late Thursday shortly after the WHO released its findings.

    The International Agency for Research on Cancer, a WHO body, found a possible link between aspartame and a type of liver cancer called hepatocellular carcinoma after reviewing three large human studies in the U.S. and Europe.
    Aspartame is used as a substitute for sugar in about 6,000 products worldwide, according to the Calorie Control Council, a trade group that represents the manufacturers of artificial sweeteners.
    Artificially sweetened beverages have historically been the biggest source of exposure to aspartame. The sugar substitute is used in diet sodas such as Diet Coke and Pepsi Zero Sugar.
    Aspartame is widely used because it is 200 times sweeter than sugar, which means beverages containing the substitute taste similar to products with sugar, but have a lower calorie count.
    Dr. Mary Schubauer-Berigan, a senior official at IARC, emphasized that the WHO classification of aspartame as a possible carcinogen is based on limited evidence.

    CNBC Health & Science

    Read CNBC’s latest health coverage:

    Schubauer-Berigan acknowledged during a news conference with journalists Wednesday that the studies could contain flaws that skewed the results. She said the classification should be viewed as a call to conduct more research into whether aspartame can cause cancer in humans.
    “This shouldn’t really be taken as a direct statement that indicates that there is a known cancer hazard from consuming aspartame,” Schubauer-Berigan said.
    The FDA spokesperson said the classification of aspartame as “possibly carcinogenic to humans” does not mean the sugar substitute is actually linked to cancer. Health Canada and the European Food Safety Authority have also concluded that aspartame is safe at the current permitted levels, the spokesperson said.
    A separate body of international scientists called the Joint Expert Committee on Food Additives said Thursday that the evidence of an association between aspartame and cancer in humans is not convincing. JECFA is an international group made up of scientists from the WHO and the U.N. Food and Agriculture Organization.
    JECFA makes recommendations about how much of a product people can safely consume. The organization maintained its recommendation that it is safe for a person to consume 40 milligrams of aspartame per kilogram of body weight daily during their lifetime.
    An adult who weighs 70 kilograms, or 154 pounds, would have to drink more than nine to 14 cans of aspartame-containing soda daily to exceed the limit and potentially face health risks.
    The U.S. Health and Human Services Department told the WHO in an August 2022 letter that JECFA is better suited to provide public health recommendations about the safety of aspartame in food.
    This is because JECFA reviews all available data, both public and private proprietary information, whereas the IARC only looks at public data.
    “Thus, an IARC review of aspartame, by comparison, would be incomplete and its conclusion could be confusing to consumers,” Mara Burr, who heads the HHS office of multilateral relations, wrote in the letter.
    The FDA has a slightly higher recommendation than JECFA and says it is safe for a person to consume 50 milligrams of aspartame per kilogram of body weight daily during their lifetime. A person who weighs 132 pounds would have to consume 75 packets of aspartame per day to reach this limit. More

  • in

    Binance could lay off thousands as company buckles down for DOJ probe, source says

    Binance plans to lay off between 1,500 and 3,000 employees through the year in response to an ongoing Justice Department probe, a current employee familiar with the company’s plans told CNBC. A company spokesperson disputed the higher number.
    The company has already laid off 1,000, the Wall Street Journal reported earlier on Friday, and this number is part of the total, CNBC’s source said.
    Binance has been charged by both the SEC and CFTC with various securities and commodities violations, while founder Changpeng Zhao has downplayed concerns.

    Changpeng Zhao, billionaire and chief executive officer of Binance Holdings Ltd., speaks during a session at the Web Summit in Lisbon, Portugal, on Wednesday, Nov. 2, 2022.
    Zed Jameson | Bloomberg | Getty Images

    Crypto exchange Binance is laying off employees in response to an ongoing Justice Department probe that is likely to end with a consent decree or settlement, according to a current employee who is familiar with the company’s plans.
    The cuts will eliminate 1,500 to 3,000 of Binance’s global workforce, this person told CNBC, and will take place through the end of the year. The Wall Street Journal previously reported on Friday that 1,000 employees have already been laid off, and those layoffs are part of the total planned, the source told CNBC. This person asked to remain anonymous because they are not authorized to talk to the press about internal matters.

    related investing news

    The Justice Department probe will likely reshape the company fundamentally, the employee told CNBC. If Binance opts to settle the DOJ allegations, it could result in a multi-billion dollar payment. Reuters has reported that federal prosecutors have been weighing anti-money laundering violations and sanctions evasion charges, allegations that would make it difficult for Binance or founder Changpeng Zhao to continue to get licenses to operate.
    A Binance spokesperson disputed that the cuts would impact 3,000 employees, saying that the high-end number was “just not right.”
    The spokesperson said, “As we prepare for the next major bull cycle, it has become clear that we need to focus on talent density across the organization to ensure we remain nimble and dynamic. This is not a case of rightsizing, but rather, re-evaluating whether we have the right talent and expertise in critical roles.”
    Binance has faced significant regulatory challenges over the last few months, culminating in lawsuits from the Securities and Exchange Commission and the Commodity Futures Trading Commission over alleged mishandling of customer assets and the operation of an illegal, unregistered exchange in the U.S.
    Binance founder Changpeng Zhao has repeatedly dismissed concerns about the future of the exchange, even after being personally named in the SEC’s lawsuit. Binance itself has suffered significantly since the lawsuits from U.S. regulators, with exchange outflows running into the hundreds of millions. The company has also seen a number of key executive departures. More

  • in

    Obesity drug maker Versanis to be bought by Eli Lilly for $1.9 billion

    Eli Lilly will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to expand its weight loss treatment portfolio. 
    The deal is Eli Lilly’s latest attempt to capitalize on the weight loss industry gold rush, which began last year after Novo Nordisk’s blockbuster injections Wegovy and Ozempic boomed in popularity. 
    Oakland, California-based Versanis has once drug candidate called bimagreumab, which binds directly to certain cells in the body to reduce fat mass.

    Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
    Cristina Arias | Cover | Getty Images

    Eli Lilly on Friday said it will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to boost the pharmaceutical giant’s weight loss treatment portfolio. 
    Eli Lilly agreed to pay Versanis shareholders in cash, which will consist of an upfront payment and potentially subsequent payments if Versanis achieves certain “development and sales milestones.”

    related investing news

    2 days ago

    Oakland, California-based Versanis, which was founded in 2021 by biotech investment firm Aditum Bio, has one experimental drug for obesity and potentially other conditions.
    Eli Lilly’s stock price rose 3% on Friday following the announcement.
    The deal is Eli Lilly’s latest attempt to capitalize on the weight loss industry gold rush, which began last year after Novo Nordisk’s blockbuster injections Wegovy and Ozempic boomed in popularity. 
    An estimated 40% of U.S. adults are obese. Analysts project that the global weight loss drug market could be worth $100 billion by around 2030. 
    Versanis’ drug, bimagrumab, binds directly to certain cells in the body to reduce fat mass.

    The company is studying bimagrumab in a phase two trial in adults who are overweight or obese, and in another trial that compares the treatment with Novo Nordisk’s Wegovy and Ozempic.
    Bimagrumab works differently from Novo Nordisk’s drugs and similar treatments from Indianapolis-based Eli Lilly. Those drugs, known as GLP-1 agonists, mimic hormones produced in the gut called incretins to suppress a person’s appetite.
    But Versanis said combining bimagrumab with those incretin-based therapies could potentially lead to better outcomes for people living with obesity and cardiometabolic conditions, which includes diabetes, kidney disease and disorders affecting the heart. 

    CNBC Health & Science

    Read CNBC’s latest health coverage:

    Eli Lilly is working on several obesity treatments. 
    The company’s once-weekly experimental injection, retatrutide, helped overweight or obese patients lose up to 24% of their weight after 48 weeks.
    That surpasses the weight reduction caused by other obesity drugs.
    Eli Lilly’s experimental obesity pill, orforglipron, also helped overweight or obese patients lose up to 14.7% of their body weight after 36 weeks.
    The company is also pushing to approve its Type 2 diabetes treatment, Mounjaro, for obesity. 
    Correction: Versanis’ drug, bimagrumab, binds directly to certain cells in the body to reduce fat mass. An earlier version misspelled the name of the drug. More

  • in

    Dimon says private equity giants are ‘dancing in the streets’ over tougher bank rules

    JPMorgan Chase executives warned that tougher regulations in the wake of bank failures this year would raise costs for consumers and businesses.
    JPMorgan CEO Jamie Dimon said that other financial players could end up winners.
    “This is great news for hedge funds, private equity, private credit, Apollo, Blackstone,” Dimon said, naming two of the largest private equity players. “They’re dancing in the streets.”

    Jamie Dimon, CEO of JPMorgan Chase, testifies during the Senate Banking, Housing, and Urban Affairs Committee hearing titled Annual Oversight of the Nations Largest Banks, in Hart Building on Sept. 22, 2022.
    Tom Williams | CQ-Roll Call, Inc. | Getty Images

    JPMorgan Chase executives warned Friday that tougher regulations in the wake of a trio of bank failures this year would raise costs for consumers and businesses, while forcing lenders to exit some businesses entirely.
    When asked by Wells Fargo analyst Mike Mayo about the impact of changes proposed by Federal Reserve Vice Chair for Supervision Michael Barr in a speech earlier this week, JPMorgan CEO Jamie Dimon said that other financial players could end up winners.

    related investing news

    “This is great news for hedge funds, private equity, private credit, Apollo, Blackstone,” Dimon said, naming two of the largest private equity players. “They’re dancing in the streets.”
    Blackstone and Apollo didn’t immediately respond to requests for comment on Dimon’s remarks.
    Banks face requirements to hold more capital as a cushion against risky activities from both U.S. and international regulators. Authorities are proposing higher capital requirements for banks with at least $100 billion in assets after the sudden collapse of Silicon Valley Bank in March. But that also coincides with a long-awaited set of international rules spurred by the 2008 financial crisis referred to as the Basel III endgame.

    Rise of the shadow banks

    “How much business leaves JPMorgan or the industry if capital ratios go up as much as potentially proposed?” Mayo asked.
    CFO Jeremy Barnum said that banks would raise prices on end users of loans and other products before ultimately deciding to leave some areas entirely.

    “To the extent we have pricing power and the higher capital requirements means that we’re not generating the right return for shareholders, we will try to reprice and see how that sticks,” Barnum said.
    “If the repricing is not successful, then in some cases, we will have to remix and that means getting out of certain products and services,” he said. “That probably means that those products and services leave the regulated perimeter and go elsewhere.”
    After the 2008 financial crisis, heightened rules forced banks to pull back from activities including mortgages and student loans. For corporations and institutional players, acquisitions and other huge loans are now increasingly funded by private equity players like Blackstone and Apollo.
    That has contributed to the rise of non-bank players, sometimes referred to as the “shadow banking” industry, which has concerned some financial experts because they generally face lower federal scrutiny than banks. More

  • in

    Why Citigroup’s shift to wealth management is a risky bet

    Since the company’s collapse during the 2008 recession, Citigroup’s stock has continuously struggled.
    In response, Jane Fraser, the CEO of Citigroup, announced a bold shift in the company strategy, doubling down on wealth management.
    But despite the shift in strategy, Citigroup’s investment in wealth management hasn’t started to pay off.

    Since the company’s collapse during the 2008 recession, Citigroup’s stock has continuously struggled, with shares falling more than 30% over the past five years.
    In response, Jane Fraser, the CEO of Citigroup, announced a bold shift in company strategy, and it has exited 14 consumer markets outside of the United States since April 2021.

    “What’s been obvious to analysts for a long time is that Citi had become too unwieldy and too big to manage,” said Hugh Son, a banking reporter at CNBC. “Ultimately, a lot of the disparate parts overseas didn’t really have very many synergies between them.”
    Citigroup instead announced its plans to divert resources and double down on wealth management. It’s a tactical move that several other major banks like Bank of America and Wells Fargo have adopted in recent years.
    “It offers high returns and it creates growth opportunities in areas that are in the early stages of wealth generation like Asia and the Middle East,” according to Mike Mayo, a senior banking analyst at Wells Fargo Securities. “And it comes with less risk of big mishaps so the regulatory treatment is better.”
    Despite the shift in strategy, though, Citigroup’s investment in wealth management hasn’t started to pay off. In 2022, the firm expected global wealth management to generate a compound annual revenue growth in the high single digits to low teens.
    But, instead, Citigroup’s wealth management revenue fell 5% year over year in the second quarter of 2023.

    “It waits to be seen whether Citigroup will be successful,” said Mayo. “I’m skeptical, for as much as I am more positive about Citi’s strategy when it comes to their global payments or banking or markets business. I think it’s to be determined how this wealth management strategy plays out.”
    Citigroup declined to provide someone for CNBC to interview for this piece.
    Watch the video above to see how Citigroup is planning its comeback. More